Glaxo to ac­quire US can­cer drug firm

Yorkshire Post - Business - - NEWS -

Bio­pharma: Glax­oSmithK­line is to ac­quire on­col­ogy-fo­cused US pharma busi­ness Te­saro for £4bn. The FTSE 100-listed group will also as­sume the firm’s net debt.

Te­saro is a com­mer­cial­stage bio­pharma com­pany and its mar­keted prod­uct Ze­jula is cur­rently ap­proved for treat­ment of ovar­ian can­cer in both the US and Europe.

Ze­jula is also be­ing in­ves­ti­gated for its po­ten­tial use in breast, lung, and prostate can­cer pa­tients. The Te­saro ac­qui­si­tion is ex­pected to have a mid to high sin­gledigit im­pact on Glaxo’s ad­justed earn­ings per share for the first two years be­fore be­com­ing ac­cre­tive by 2022.

Newspapers in English

Newspapers from UK

© PressReader. All rights reserved.